The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2018 | Hot topic: optimal immunotherapy combinations for lung cancer
Now that there is a range of immunotherapies available, the next frontier to explore is immunotherapy combination regimens. In this interview, Fred Hirsch, MD, PhD, of University of Colorado, Denver, CO, discusses the optimal immunotherapy combinations for lung cancer, referencing recent or ongoing clinical trial data. Prof. Hirsch highlights results from the combination of pembrolizumab with chemotherapy in the Phase II KEYNOTE-021 (NCT02039674) and Phase III KEYNOTE-189 (NCT02578680) studies for non-small cell lung cancer (NSCLC). He also discusses immunotherapy plus immunotherapy combinations, such as that investigated in the CheckMate 032 trial (NCT01928394), of nivolumab plus ipilimumab for small cell lung cancer (SCLC), with promising results. Prof. Hirsch also touches upon potential immunotherapy plus targeted therapy regimens, as well as the therapies to use following up-front immunotherapy. This video was recorded at the British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland.
